Blocking 2-AG Breakdown Raised Brain Levels 8-Fold and Produced Cannabinoid Effects in Mice
The first selective MAGL inhibitor (JZL184) raised brain 2-AG levels eightfold in mice and produced pain relief, hypothermia, and reduced movement through CB1 receptors, demonstrating that 2-AG is a key endogenous modulator of cannabinoid-associated behaviors.
Quick Facts
What This Study Found
Researchers developed JZL184, the first potent and selective inhibitor of MAGL, the enzyme that breaks down the endocannabinoid 2-AG.
When administered to mice, JZL184 raised brain 2-AG levels eightfold without altering anandamide levels, confirming that MAGL is the primary enzyme responsible for 2-AG degradation in the brain.
Mice treated with JZL184 exhibited analgesia, hypothermia, and reduced movement, all classic cannabinoid effects that were blocked by a CB1 receptor antagonist, confirming they were mediated through the cannabinoid system.
These findings established that 2-AG endogenously modulates several behavioral processes traditionally associated with cannabis pharmacology.
Key Numbers
Brain 2-AG increased 8-fold. Anandamide levels were not altered. JZL184 produced analgesia, hypothermia, and hypomotility. All behavioral effects were CB1-dependent.
How They Did This
Preclinical pharmacological study. JZL184 was characterized biochemically for selectivity and potency against MAGL. Brain endocannabinoid levels were measured after administration. Behavioral effects (analgesia, hypothermia, hypomotility) were assessed and confirmed as CB1-dependent using a selective antagonist.
Why This Research Matters
This was the first demonstration that selectively raising 2-AG levels produces a broad array of cannabinoid-like effects, establishing 2-AG as a major player in endocannabinoid signaling and opening new therapeutic possibilities.
The Bigger Picture
Before this study, the relative contributions of anandamide versus 2-AG to cannabinoid-associated behaviors were unclear. By selectively raising 2-AG, researchers showed it modulates core cannabinoid behaviors, fundamentally advancing understanding of endocannabinoid pharmacology.
What This Study Doesn't Tell Us
Animal study using acute dosing only. Long-term effects and potential tolerance development were not examined. The relationship between mouse behavioral effects and human therapeutic outcomes is uncertain.
Questions This Raises
- ?Does tolerance develop to the effects of chronic MAGL inhibition?
- ?Could MAGL inhibitors serve as alternatives to cannabis for pain management?
- ?What are the side effect profiles compared to direct CB1 agonists?
Trust & Context
- Key Stat:
- Brain 2-AG increased 8-fold with no change in anandamide
- Evidence Grade:
- Landmark preclinical study published in Nature Chemical Biology with rigorous biochemical and behavioral characterization. Limited to animal models.
- Study Age:
- Published in 2009. This was a foundational study that enabled much subsequent endocannabinoid research. MAGL inhibitors have since been developed for clinical testing.
- Original Title:
- Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects.
- Published In:
- Nature chemical biology, 5(1), 37-44 (2009)
- Authors:
- Long, Jonathan Z(7), Li, Weiwei, Booker, Lamont(2), Burston, James J, Kinsey, Steven G, Schlosburg, Joel E, Pavón, Franciso J, Serrano, Antonia M, Selley, Dana E, Parsons, Loren H, Lichtman, Aron H, Cravatt, Benjamin F
- Database ID:
- RTHC-00371
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is 2-AG?
2-arachidonoylglycerol (2-AG) is one of the two main endocannabinoids, molecules naturally produced in the brain that activate cannabinoid receptors. This study showed it is the more abundant of the two and plays a central role in cannabinoid signaling.
Could this lead to new medications?
Potentially. MAGL inhibitors raise the body's own cannabinoid levels rather than introducing external cannabinoids, which could provide therapeutic benefits with a different side effect profile than THC or other direct cannabinoid agonists.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-00371APA
Long, Jonathan Z; Li, Weiwei; Booker, Lamont; Burston, James J; Kinsey, Steven G; Schlosburg, Joel E; Pavón, Franciso J; Serrano, Antonia M; Selley, Dana E; Parsons, Loren H; Lichtman, Aron H; Cravatt, Benjamin F. (2009). Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects.. Nature chemical biology, 5(1), 37-44. https://doi.org/10.1038/nchembio.129
MLA
Long, Jonathan Z, et al. "Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects.." Nature chemical biology, 2009. https://doi.org/10.1038/nchembio.129
RethinkTHC
RethinkTHC Research Database. "Selective blockade of 2-arachidonoylglycerol hydrolysis prod..." RTHC-00371. Retrieved from https://rethinkthc.com/research/long-2009-selective-blockade-of-2arachidonoylglycerol
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.